Jinman Zhong

Jinman Zhong

Auto-generated profile, based on publicly available information

Jinman Zhong

Department of Radiology, The Second Affiliated Hospital, Xi’ an Jiaotong University, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2024 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
JZJinman Zhong
Jinman Zhong
DLDuoduo Liu
Duoduo Liu
QYQuanxin Yang
Quanxin Yang
JDJianke Ding
Jianke Ding
XCXin Chen
Xin Chen
Background: Early recognition of castration-resistant state is of significance for timely adjustment of treatment regimens and improvement of prognosis. Purpose: This study aims to screen new aptamers CRda8 and CRda21 which recognize castration resistant prostate cancer (CRPC) cells with high affinity and specificity by SELEX technology. Methods: The enrichment of specific aptamer candidates was monitored by flow cytometric analysis. The affinity and specificity of aptamer candidates were evaluated by flow cytometry and immunofluorescence assay. MR imaging of CRda21-conjugated polyethylene glycol (PEG)-Fe3O4 nanoparticles to CRPC was further explored in vivo. Results: Both aptamers showed high specificity to target cells with dissociation constants in the nanomolar range, and did not recognize other tested cells. The staining of clinical tissue sections with fluorescent dye labeled aptamers showed that sections from CRPC exhibited stronger fluorescence while sections from benign prostatic hyperplasia and androgen dependent prostate cancer did not exhibit notable fluorescence. In vivo MRI demonstrated that CRda21-conjugated PEG-Fe3O4 had good affinity to CRPC and produced strong T2WI signal intensity reduction distinguished from peritumoral tissue. Conclusion: The high affinity and specificity of CRda8 and CRda21 make the aptamer hold potential for early recognition of castration-resistant state and diagnosis of CRPC at the cellular level.

1 January 2020 in Korean Journal of Radiology
Verified
Journal Article
Open access
PDF file
JZJinman Zhong
Jinman Zhong
WQWeijun Qin
Weijun Qin
YLYu Li
Yu Li
YWYang Wang
Yang Wang
YHYi Huan
Yi Huan
RJRen Jing
Ren Jing
Zhong J, et al. Korean J Radiol. 2020 Jul;21:e132. https://doi.org/10.3348/kjr.2019.0820

8 January 2026 in British Journal of Radiology
Verified
Journal Article
Closed access
JZJinman Zhong
Jinman Zhong
ZCZhiwen Che
Zhiwen Che
XQXingru Qin
Xingru Qin
YZYuelang Zhang
Yuelang Zhang
QYQuanxin Yang
Quanxin Yang
JDJianke Ding
Jianke Ding
Objectives: To investigate the value of combining zonal origin with intravoxel incoherent motion (IVIM) parameters in predicting the International Society of Urological Pathology (ISUP) risk groups of prostate cancer. Methods: The retrospective study enrolled 351 prostate cancer patients who underwent mpMRI including IVIM. Patients were stratified into low-risk and high-risk group according to ISUP grades, and divided into peripheral zone (PZ) and transition zone (TZ) cancer group according to zonal origins of lesions. Clinicopathological characteristics and IVIM-derived parameters between groups were compared. Logistic regression was performed to identify variables associated with ISUP high-risk group. The predictive accuracy of the variables for ISUP risk groups was evaluated using receiver operating characteristic (ROC) analysis. Results: PZ cancers exhibited higher proportion of pathological stage ≥pT3 (P = .0184) and ISUP grade 3-5 (P < .0001), and demonstrated lower Dmean, ADCmin, and ADCmean (P = .0209, P = .0160, P = .0302) than TZ cancers. There was significant differences in zonal origin, Dmean, ADCmin, and ADCmean between the 2 ISUP risk groups (P < .0001, P < .0001, P = .0024, P = .0017). Zonal origin, prostate-specific antigen (PSA), Dmean, and ADCmin were identified as independent predictors of ISUP high-risk disease. The comprehensive model combining zonal origin, PSA, Dmean, and ADCmin demonstrated superior predictive performance (AUC = 0.956, 95% CI: 0.930-0.981) with a sensitivity of 90.63% and a specificity of 76.04%. Conclusions: The combined diagnostic model demonstrates high efficiency for predicting the ISUP risk group preoperatively for prostate cancer. Advances in knowledge: The multiparameter predictive model including anatomical zones offers a non-invasive and effective tool for preoperative risk stratification for prostate cancer, thereby improving decision-making precision, and reducing unnecessary invasive procedures.

3 April 2026 in Archives of Medical Science
Verified
Journal Article
Open access
PDF file
JZJinman Zhong
Jinman Zhong
JDJianke Ding
Jianke Ding
YZYuelang Zhang
Yuelang Zhang
QYQuanxin Yang
Quanxin Yang
Introduction: Transition zone (TZ) prostate cancer poses diagnostic challenges due to overlapping imaging features with benign prostatic hyperplasia (BPH). The study aims to investigate whether Prostate Imaging Reporting and Data System (PI-RADS) v2.1 combined with prostate-specific antigen density (PSAD) can enhance diagnostic accuracy in distinguishing TZ cancer from BPH. Material and methods: The retrospective study included 377 patients divided into two groups: TZ cancer group (n = 139) and BPH group (n = 238). Two radiologists independently reviewed prostate MR images of each patient and assigned a PI-RADS score for the TZ lesion. Clinical characteristics between the two groups were compared using Chi-square test, t-test or Mann-Whitney U-test. The diagnostic performance of PI-RADS scores, PSAD and the combined parameters was determined by ROC curve analysis. Results: Statistically significant differences were found in PSA, prostate volume, PSAD and PI-RADS scores between the two groups (All P  0.0001). No difference in age was observed between the two groups (P = 0.602). The area under the curve (AUC) for PI-RADS v2.1 alone was 0.802 (95% CI: 0.759-0.841) with a sensitivity of 79.14% and specificity of 74.37% at a cutoff of  4. The AUC for PSAD alone was 0.808 (95% CI: 0.765-0.847) with a sensitivity of 79.14% and specificity of 77.31% at a cutoff of 0.22 ng/mL/mL. Combining PI-RADS and PSAD yielded an AUC of 0.873 (95% CI: 0.835-0.905), with a sensitivity of 79.26% and specificity of 86.55%. Conclusions: The combination of PI-RADS v2.1 and PSAD enhances the diagnostic accuracy for TZ cancer, thereby reducing unnecessary invasive procedure.